Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(1 year, 10 months ago) | |
US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(1 year, 7 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6890927 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(1 year, 4 months ago) | |
US7265119 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(1 year, 1 month ago) |
Chantix is owned by Pf Prism Cv.
Chantix contains Varenicline Tartrate.
Chantix has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Chantix are:
Chantix was authorised for market use on 10 May, 2006.
Chantix is available in tablet;oral dosage forms.
Chantix can be used as aid to smoking cessation.
The generics of Chantix are possible to be released after 03 February, 2023.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Feb 22, 2022 |
Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL